{"id":"motavizumab-medi-524","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1743042","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to the F-protein on the surface of RSV, preventing the virus from entering host cells and causing infection. This mechanism of action is specific to RSV and does not affect other viruses or pathogens.","oneSentence":"Motavizumab is a monoclonal antibody that targets the respiratory syncytial virus (RSV) F-protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:22:03.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease"}]},"trialDetails":[{"nctId":"NCT00121108","phase":"PHASE3","title":"MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2004-11-15","conditions":"Healthy","enrollment":2127},{"nctId":"NCT00192504","phase":"PHASE1","title":"Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2004-03","conditions":"Respiratory Syncytial Virus Prophylaxis","enrollment":31},{"nctId":"NCT00421304","phase":"NA","title":"A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2007-01-10","conditions":"RSV Illness in ≤12 Months of Participants","enrollment":118},{"nctId":"NCT00435227","phase":"PHASE2","title":"A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness","status":"TERMINATED","sponsor":"MedImmune LLC","startDate":"2007-03-20","conditions":"Participants Less Than 12 Months of Age With RSV Illness","enrollment":12},{"nctId":"NCT00129766","phase":"PHASE3","title":"Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2004-11","conditions":"Respiratory Syncytial Virus Infections","enrollment":6635},{"nctId":"NCT00113490","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2005-05","conditions":"Motavizumab Administration for a Second Season for RSV Prophylaxis","enrollment":136},{"nctId":"NCT00316264","phase":"PHASE2","title":"Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2006-04","conditions":"Respiratory Syncytial Virus Infections, Chronic Lung Disease and <= 24 Months of Age or, Premature With Gestational Age <=35 Weeks and <=6 Months of Age","enrollment":260},{"nctId":"NCT00628303","phase":"PHASE3","title":"A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants","status":"WITHDRAWN","sponsor":"MedImmune LLC","startDate":"2010-10","conditions":"Wheezing","enrollment":""},{"nctId":"NCT00538785","phase":"PHASE2","title":"A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2005-10","conditions":"Congenital Heart Disease","enrollment":1236},{"nctId":"NCT00192465","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2003-11","conditions":"Respiratory Syncytial Virus Infections","enrollment":30},{"nctId":"NCT00192478","phase":"PHASE1, PHASE2","title":"Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2004-02","conditions":"Respiratory Syncytial Virus Infections","enrollment":217}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MEDI-524","motavizumab","Rezield"],"phase":"phase_3","status":"active","brandName":"motavizumab (MEDI-524)","genericName":"motavizumab (MEDI-524)","companyName":"MedImmune LLC","companyId":"medimmune-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Motavizumab is a monoclonal antibody that targets the respiratory syncytial virus (RSV) F-protein. Used for Prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}